CAS NO: | 88495-63-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
生物活性 | Artesunate is an inhibitor of bothSTAT-3andexported protein 1(EXP1). | ||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||
体外研究 (In Vitro) | Artesunate is an inhibitor of both STAT-3[1]and exported protein 1 (EXP1)[2]. Artesunate treatment for 24 h causes a significant increase in the levels of reactive oxygen species (ROS) in a dose-dependent manner in both cell lines. Moreover, Western blotting shows that the levels ofγ-H2AX are significantly elevated when cancer cells are treated with Artesunate in the higher dose range for 24 h. Artesunate also shows a time-dependent effect on the level of RAD51 in A2780 and HO8910 cells. In two types of non-malignant cells, normal human fibroblasts and immortalized epithelial cells, FTE-187, the level of RAD51 is not altered by Artesunate. In A2780 cells, the level of RAD51 mRNA is indeed decreased by the addition of Artesunate, in a dose-dependent manner. Correspondingly, the promoter activity of RAD51 is significantly inhibited by Artesunate. In contrast, the RAD51 mRNA level in H8910 cells is not affected by Artesunate[3]. | ||||||||||||||||
体内研究 (In Vivo) | Tumor growth is significantly reduced in the group receiving combined treatment of Artesunate and cisplatin (P<0.01). In comparison, Artesunate alone has no significant effect on the growth of tumor xenografts for both cell lines[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 384.42 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C19H28O8 | ||||||||||||||||
CAS 号 | 88495-63-0 | ||||||||||||||||
中文名称 | 青蒿酯;青蒿琥酯;二氢青蒿素-12-α-丁二酸单酯; | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 83.33 mg/mL(216.77 mM;Need ultrasonic) 7.5% sodium bicarbonate : 20 mg/mL(52.03 mM;Need ultrasonic) H2O : 0.67 mg/mL(1.74 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|